A Study in Men With Low Testosterone to Measure the Effects of Testosterone Solution on Testosterone Levels, Sex Drive and Energy

Inclusion Criteria:

- Total testosterone level <300 nanogram per deciliter (ng/dL) [10.4 nanomole per Liter
(nmol/L)] at each of 2 screening visits

- At least 1 symptom of testosterone deficiency, which must include decreased energy or
decreased sexual drive

- Prostate Specific Antigen (PSA) <4 nanogram per milliliter (ng/ml) at screening

Exclusion Criteria:

- Sexual partner who is or becomes pregnant at any time during the study

- Use of long-acting intramuscular (IM) testosterone undecanoate or testosterone
pellets in the 6-month period prior to screening

- Body Mass Index (BMI) >37 kilogram per square meter (kg/m^2) at screening

- Severe lower urinary tract symptoms and/or significant prostate enlargement

- Prolactin lab test result of >30 ng/mL at screening

- Hemoglobin A1c (HbA1c) >11% at screening

- Hematocrit ≥50% (>54% at elevated altitude) at screening

- Current use of any medications, herbal, and/or nutritional supplements that can
interfere with testosterone

- Dermatologic condition in underarm area that might interfere with testosterone
absorption (for example, eczema) or be exacerbated by topical testosterone
replacement therapy

- Currently receiving treatment with cancer chemotherapy or antiandrogens

- Chronic use of systemic glucocorticoids (use for >14 days within the 3 months prior
to screening); use of non-testosterone anabolic steroids within 12 months prior to
screening

- Competitive athletes involved in a sport in which they may be screened for anabolic
steroids

- History of use of estrogenizing agents within 12 months prior to screening

- History of luteinizing hormone-releasing hormone antagonist or agonist treatment in
the last 6 months prior to screening

- History of clomiphene or other anti-estrogen treatment in the 3 months prior to
screening

- Use of finasteride within 3 months prior to screening, or use of dutasteride within 6
months prior to screening

- Current use of warfarin or phenprocoumon

- History of frequent opioid use: >1 time/week during any week within 30 days prior to
screening

- Current use of dopamine receptor agonists (cabergoline, pergolide, bromocriptine)

- Have a history of significant central nervous system injuries or disease (including
stroke, spinal cord injury, or multiple sclerosis) within 6 months prior to screening

- Systolic blood pressure >170 or <90 millimeter of mercury (mm Hg) or diastolic blood
pressure >100 or <50 mm Hg at screening or a history of malignant hypertension

- History of unstable angina as defined by Braunwald Classification of Unstable Angina
or angina occurring during sexual intercourse in the last 6 months

- History of any of the following coronary conditions within 90 days of screening:
myocardial infarction, coronary artery bypass graft surgery, percutaneous coronary
intervention (angioplasty or stent placement)

- Have any supraventricular arrhythmia with an uncontrolled ventricular response [mean
heart rate >100 beats per minute (bpm)] at rest, or have any history of spontaneous
or induced sustained ventricular tachycardia (heart rate >100 bpm for ≥30 seconds),
or use of an automatic internal cardioverter-defibrillator

- Have a history of sudden cardiac arrest

- Exhibit any evidence of congestive heart failure [New York Heart Association (NYHA)
Class 2 or above], within 6 months prior to screening

- Have had a new, significant cardiac conduction defect within 90 days prior to
screening

- Clinical suspicion (or history) of prostate cancer during digital rectal examination
at screening

- Known or suspected breast cancer (or history of breast cancer) or other active cancer
(with the exception of nonmelanotic skin cancer)

- Exhibit evidence of severe renal impairment [creatinine clearance <30 milliliter per
minute (mL/min) as determined by the Cockcroft-Gault formula] at screening

- Exhibit a history of severe liver disease or clinical evidence of hepatic impairment
at screening

- Have a history of human immunodeficiency virus (HIV) infection

- Severe sleep apnea

- Untreated hypothyroidism, hypercortisolism or other significant endocrinopathy (other
than hypogonadism) that contributes to symptoms of low energy or fatigue